Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents

Immune therapy improves cancer outcomes, yet many patients do not respond. This pre-clinical study investigated whether vascular disrupting agents (VDAs) could convert an immune unresponsive tumor into a responder. CDF1 mice, with 200 mm(3) C3H mammary carcinomas in the right rear foot, were intrape...

Descripción completa

Detalles Bibliográficos
Autores principales: Horsman, Michael R., Wittenborn, Thomas R., Nielsen, Patricia S., Elming, Pernille B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370297/
https://www.ncbi.nlm.nih.gov/pubmed/32640548
http://dx.doi.org/10.3390/ijms21134778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370297/
https://www.ncbi.nlm.nih.gov/pubmed/32640548
http://dx.doi.org/10.3390/ijms21134778

Ejemplares similares